تعديل

jeudi 24 mars 2016

Portola's long-acting blood thinner misses main goal in study

(Reuters) - Portola Pharmaceuticals Inc said late-stage data showed its oral anticoagulant was not superior to an injectable standard therapy in preventing blood clots in acutely ill patients.











http://ift.tt/1WKS95b

from Reuters: Health News
via animenewspro

Aucun commentaire:

Enregistrer un commentaire